Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Carcinoma, Transitional Cell 15Neoplasms 14Ovarian Neoplasms 13Carcinoma, Renal Cell 13Urinary Bladder Neoplasms 12Carcinoma, Merkel Cell 12Squamous Cell Carcinoma of Head and Neck 11Colorectal Neoplasms 8Triple Negative Breast Neoplasms 7Pancreatic Neoplasms 7Neoplasm Metastasis 7Melanoma 7Stomach Neoplasms 6Recurrence 5Breast Neoplasms 5Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Lymphoma, Non-Hodgkin 2Kidney Neoplasms 2Kidney Diseases 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Ovarian Epithelial 2Uveal Melanoma 1Urothelial Cancer 1

Interventions

Rituximab 90Cyclophosphamide 30Lenalidomide 28Bendamustine Hydrochloride 24Prednisone 20Vincristine 19obinutuzumab 17Doxorubicin 16fludarabine 14ibrutinib 13tazemetostat 9idelalisib 9Deoxycholic Acid 9parsaclisib 8Prednisolone 8zanubrutinib 7venetoclax 7tofacitinib 7tisagenlecleucel 5pembrolizumab 5ofatumumab 5ibritumomab tiuxetan 5duvelisib 5Gemcitabine 5Bortezomib 5durvalumab 4aflibercept 4R-CHOP protocol 4Methylprednisolone 4Methotrexate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Follicular × avelumab × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡